Do analysts rate ASLN or INM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate REVB or ASLN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is REVB or ASLN more profitable?

Revelation Biosciences' return on equity of -100.19% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Revelation Biosciences N/A -100.19% -82.72% ASLAN Pharmaceuticals N/A -8,454.87% -121.60%

Do analysts recommend ASLN or SILO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Silo Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend ASLN or APM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, ASLN or APM?

Aptorum Group has lower revenue, but higher earnings than ASLAN Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ASLAN Pharmaceuticals $12M 0.10 -$44.22M -$21.92 N/A Aptorum Group $430K 9.86 -$1.36M N/A N/A

Is ASLN or APM more profitable?

Aptorum Group's return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ASLAN Pharmaceuticals N/A -8,454.87% -121.60% Aptorum Group N/A N/A N/A

Is ASLN or LIAN more profitable?

LianBio's return on equity of -33.17% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ASLAN Pharmaceuticals N/A -8,454.87% -121.60% LianBio N/A -33.17% -30.19%

ASLAN Pharmaceuticals (ASLN) Competitors

$0.60 0.00 (0.00%)

As of 08/24/2026

Compare

ASLN vs. INM, REVB, SILO, APM, and LIAN

Should you buy ASLAN Pharmaceuticals stock or one of its competitors? ASLAN Pharmaceuticals's main competitors and comparable companies include InMed Pharmaceuticals (INM), Revelation Biosciences (REVB), Silo Pharma (SILO), Aptorum Group (APM), and LianBio (LIAN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ASLAN Pharmaceuticals compare to InMed Pharmaceuticals?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, ASLAN Pharmaceuticals' average media sentiment score of 0.00 equaled InMed Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
ASLAN Pharmaceuticals	Neutral
InMed Pharmaceuticals	Neutral

58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

InMed Pharmaceuticals has lower revenue, but higher earnings than ASLAN Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A
InMed Pharmaceuticals	$4.94M	0.97	-$8.16M	-$2.89	N/A

ASLAN Pharmaceuticals has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. InMed Pharmaceuticals' return on equity of -80.85% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%

ASLAN Pharmaceuticals has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Summary

ASLAN Pharmaceuticals and InMed Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to Revelation Biosciences?

Revelation Biosciences (NASDAQ:REVB) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Revelation Biosciences has higher earnings, but lower revenue than ASLAN Pharmaceuticals. Revelation Biosciences is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revelation Biosciences	N/A	N/A	-$8.91M	-$12.31	N/A
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A

Revelation Biosciences' return on equity of -100.19% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revelation Biosciences	N/A	-100.19%	-82.72%
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Revelation Biosciences has a beta of -0.15, meaning that its stock price is 115% less volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

In the previous week, Revelation Biosciences had 1 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 1 mentions for Revelation Biosciences and 0 mentions for ASLAN Pharmaceuticals. Revelation Biosciences' average media sentiment score of 0.00 equaled ASLAN Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Revelation Biosciences	Neutral
ASLAN Pharmaceuticals	Neutral

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 4.8% of Revelation Biosciences shares are held by insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Revelation Biosciences beats ASLAN Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to Silo Pharma?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and Silo Pharma (NASDAQ:SILO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. Comparatively, 5.6% of Silo Pharma shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by company insiders. Comparatively, 3.6% of Silo Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Silo Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ASLAN Pharmaceuticals has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Silo Pharma has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market.

ASLAN Pharmaceuticals has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. Silo Pharma's return on equity of -81.75% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
Silo Pharma	-6,726.39%	-81.75%	-66.35%

Silo Pharma has lower revenue, but higher earnings than ASLAN Pharmaceuticals. Silo Pharma is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A
Silo Pharma	$54.08K	75.79	-$4.23M	-$4.36	N/A

In the previous week, Silo Pharma had 3 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 3 mentions for Silo Pharma and 0 mentions for ASLAN Pharmaceuticals. ASLAN Pharmaceuticals' average media sentiment score of 0.00 beat Silo Pharma's score of -0.20 indicating that ASLAN Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
ASLAN Pharmaceuticals	Neutral
Silo Pharma	Neutral

Summary

ASLAN Pharmaceuticals and Silo Pharma tied by winning 7 of the 14 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to Aptorum Group?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and Aptorum Group (NASDAQ:APM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.8% of Aptorum Group shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by company insiders. Comparatively, 64.0% of Aptorum Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Aptorum Group's return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
Aptorum Group	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, ASLAN Pharmaceuticals' average media sentiment score of 0.00 equaled Aptorum Group'saverage media sentiment score.

Company	Overall Sentiment
ASLAN Pharmaceuticals	Neutral
Aptorum Group	Neutral

ASLAN Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Aptorum Group has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Aptorum Group has lower revenue, but higher earnings than ASLAN Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A
Aptorum Group	$430K	9.86	-$1.36M	N/A	N/A

Summary

Aptorum Group beats ASLAN Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to LianBio?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and LianBio (NASDAQ:LIAN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

LianBio's return on equity of -33.17% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
LianBio	N/A	-33.17%	-30.19%

In the previous week, ASLAN Pharmaceuticals' average media sentiment score of 0.00 equaled LianBio'saverage media sentiment score.

Company	Overall Sentiment
ASLAN Pharmaceuticals	Neutral
LianBio	Neutral

ASLAN Pharmaceuticals has higher revenue and earnings than LianBio. LianBio is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

ASLAN Pharmaceuticals has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, LianBio has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market.

58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by company insiders. Comparatively, 7.6% of LianBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

LianBio beats ASLAN Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Get ASLAN Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASLN vs. The Competition

Export

Metric	ASLAN Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.23M	$12.52B	$7.32B	$12.76B
Dividend Yield	N/A	2.61%	2.54%	10.78%
P/E Ratio	-0.03	778.08	271.18	24.19
Price / Sales	0.10	956.46	697.49	127.82
Price / Cash	N/A	15.47	29.03	36.89
Price / Book	-0.09	10.54	11.25	6.50
Net Income	-$44.22M	$2.79B	$3.45B	$347.63M
7 Day Performance	N/A	2.75%	2.90%	1.49%
1 Month Performance	N/A	5.62%	8.56%	5.12%
1 Year Performance	N/A	8.64%	27.78%	17.81%

ASLAN Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASLN ASLAN Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$1.23M	$12M	N/A	30
INM InMed Pharmaceuticals	1.2294 of 5 stars	$1.44 -1.4%	N/A	-37.3%	$4.84M	$4.94M	N/A	10	Positive News
REVB Revelation Biosciences	0.5342 of 5 stars	$1.11 -1.8%	N/A	-90.6%	$4.50M	N/A	N/A	10	Positive News Gap Down
SILO Silo Pharma	0.4891 of 5 stars	$3.10 -12.9%	N/A	-72.7%	$4.46M	$72.10K	N/A	2	Gap Down High Trading Volume
APM Aptorum Group	0.4012 of 5 stars	$0.67 -4.6%	N/A	-97.5%	$4.24M	$430K	N/A	30	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASLN) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ASLAN Pharmaceuticals (ASLN) Competitors

ASLN vs. INM, REVB, SILO, APM, and LIAN

How does ASLAN Pharmaceuticals compare to InMed Pharmaceuticals?

Summary

How does ASLAN Pharmaceuticals compare to Revelation Biosciences?

Summary

How does ASLAN Pharmaceuticals compare to Silo Pharma?

Summary

How does ASLAN Pharmaceuticals compare to Aptorum Group?

Summary

How does ASLAN Pharmaceuticals compare to LianBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASLN vs. The Competition

ASLAN Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ASLAN Pharmaceuticals (ASLN) Competitors

ASLN vs. INM, REVB, SILO, APM, and LIAN

How does ASLAN Pharmaceuticals compare to InMed Pharmaceuticals?

Do analysts rate ASLN or INM?

Does the media refer more to ASLN or INM?

Do insiders and institutionals believe in ASLN or INM?

Which has preferable valuation & earnings, ASLN or INM?

Is ASLN or INM more profitable?

Which has more volatility & risk, ASLN or INM?

Summary

How does ASLAN Pharmaceuticals compare to Revelation Biosciences?

Which has better valuation and earnings, REVB or ASLN?

Is REVB or ASLN more profitable?

Do analysts rate REVB or ASLN?

Which has more risk & volatility, REVB or ASLN?

Does the media prefer REVB or ASLN?

Do institutionals and insiders believe in REVB or ASLN?

Summary

How does ASLAN Pharmaceuticals compare to Silo Pharma?

Do insiders & institutionals hold more shares of ASLN or SILO?

Do analysts recommend ASLN or SILO?

Which has more risk and volatility, ASLN or SILO?

Is ASLN or SILO more profitable?

Which has better earnings and valuation, ASLN or SILO?

Does the media refer more to ASLN or SILO?

Summary

How does ASLAN Pharmaceuticals compare to Aptorum Group?

Do institutionals & insiders believe in ASLN or APM?

Is ASLN or APM more profitable?

Do analysts recommend ASLN or APM?

Does the media refer more to ASLN or APM?

Which has more volatility & risk, ASLN or APM?

Which has preferable valuation & earnings, ASLN or APM?

Summary

How does ASLAN Pharmaceuticals compare to LianBio?

Is ASLN or LIAN more profitable?

Does the media favor ASLN or LIAN?

Which has preferable earnings & valuation, ASLN or LIAN?

Which has more risk and volatility, ASLN or LIAN?

Do institutionals and insiders hold more shares of ASLN or LIAN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASLN vs. The Competition

ASLAN Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools